Skip to main content
SpringerLink
Log in

Mesenchymal Stem Cells as Therapy for Graft Versus Host Disease: What Have We Learned?

  • Chapter
  • First Online:
Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation

  • 1544 Accesses

Abstract

Mesenchymal stem cells (MSC) are a population of phenotypically heterogeneous cells that are one component of the supportive, stromal micro-­environment. They can be isolated from many readily accessible tissues including bone marrow, umbilical cord, placenta, and adipose tissue, and extensive ex vivo and pre-clinical data suggest that subpopulations within MSC contribute to the immunomodulation of the host, without provoking an allo-reactive T cell response. Furthermore, largely through paracrine effects, they contribute to tissue repair. These unique properties make MSC an ideal agent to investigate for the therapy of graft versus host disease (GvHD). Therapeutic trials with varied MSC dosing schedules and clinical endpoints have shown mixed results. In this chapter, we will review recent preclinical data, and summarize the results of clinical trials utilizing MSC for the treatment of acute and chronic GvHD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41–9. Epub 2002/06/22.

    Article  PubMed  CAS  Google Scholar 

  2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.

    Article  PubMed  CAS  Google Scholar 

  3. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393–5.

    Article  PubMed  CAS  Google Scholar 

  4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.

    Article  PubMed  CAS  Google Scholar 

  5. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37(4):359–66. Epub 2006/01/10.

    Article  PubMed  CAS  Google Scholar 

  6. McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6(4):311–7. Epub 2005/09/09.

    Article  PubMed  CAS  Google Scholar 

  7. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton’s jelly and bone marrow sources. Cell Immunol. 2010;264(2):171–9. Epub 2010/07/14.

    Article  PubMed  CAS  Google Scholar 

  8. Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, et al. Adipose-tissue-­derived and Wharton’s jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16(11):3537–46. Epub 2010/07/06.

    Article  PubMed  CAS  Google Scholar 

  9. Majore I, Moretti P, Stahl F, Hass R, Kasper C. Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. 2011;7(1):17–31. Epub 2010/07/03.

    Article  PubMed  Google Scholar 

  10. Tong CK, Vellasamy S, Tan BC, Abdullah M, Vidyadaran S, Seow HF, et al. Generation of mesenchymal stem cell from human umbilical cord tissue using combination of enzymatic and mechanical disassociation method. Cell Biol Int. 2011;33(3):211–6. Epub 2010/10/16.

    Google Scholar 

  11. Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B, et al. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004;32(7):657–64. Epub 2004/07/13.

    Article  PubMed  CAS  Google Scholar 

  12. Ringden O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, et al. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells. 2013;31(3):592–601. Epub 2013/01/12.

    Article  PubMed  CAS  Google Scholar 

  13. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11–20. Epub 2003/01/25.

    Article  PubMed  Google Scholar 

  14. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838–43. Epub 2002/05/03.

    Article  PubMed  Google Scholar 

  15. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22. Epub 2004/10/21.

    Article  PubMed  CAS  Google Scholar 

  16. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726–36. Epub 2009/01/28.

    Article  PubMed  CAS  Google Scholar 

  17. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251(2):131–6. Epub 2008/05/27.

    Article  PubMed  CAS  Google Scholar 

  18. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28(8):875–84. Epub 2000/09/16.

    Article  PubMed  CAS  Google Scholar 

  19. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93–8. Epub 2002/01/05.

    Article  PubMed  Google Scholar 

  20. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932–7. Epub 2002/06/27.

    Article  PubMed  CAS  Google Scholar 

  21. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108–14. Epub 2002/10/18.

    Article  PubMed  CAS  Google Scholar 

  22. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2011;11(4):473–87. Epub 2011/01/29.

    Article  PubMed  Google Scholar 

  23. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61. Epub 2009/03/14.

    Article  PubMed  CAS  Google Scholar 

  24. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411(6835):385–9. Epub 2001/05/18.

    Article  PubMed  CAS  Google Scholar 

  25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8. Epub 1995/06/01.

    PubMed  CAS  Google Scholar 

  26. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57(2):267–76. Epub 1981/02/01.

    PubMed  CAS  Google Scholar 

  27. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-­host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56. Epub 2005/12/13.

    Article  PubMed  Google Scholar 

  28. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729–35.

    Article  PubMed  CAS  Google Scholar 

  29. Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood. 1988;71(2):293–8.

    PubMed  CAS  Google Scholar 

  30. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92(7):2303–14.

    PubMed  CAS  Google Scholar 

  31. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062–8.

    PubMed  CAS  Google Scholar 

  32. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol. 2007;137(2):87–98.

    Article  PubMed  CAS  Google Scholar 

  33. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76(8):1464–72.

    PubMed  CAS  Google Scholar 

  34. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7):387–94.

    Article  PubMed  CAS  Google Scholar 

  35. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114(3):511–7. Epub 2009/05/16.

    Article  PubMed  CAS  Google Scholar 

  36. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92(7):2288–93. Epub 1998/09/25.

    PubMed  Google Scholar 

  37. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6(4A):441–7.

    Article  PubMed  CAS  Google Scholar 

  38. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr PL, et al. Effect of up-­front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104(5):1559–64.

    Article  PubMed  CAS  Google Scholar 

  39. Deeg HJ. How I, treat refractory acute GVHD. Blood. 2007;109(10):4119–26. Epub 2007/01/20.

    Article  PubMed  CAS  Google Scholar 

  40. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013;91(1):19–26. Epub 2012/10/24.

    Article  PubMed  CAS  Google Scholar 

  41. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010;5(4):e10088. Epub 2010/05/04.

    Article  PubMed  Google Scholar 

  42. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27(4):909–19. Epub 2009/04/09.

    Article  PubMed  CAS  Google Scholar 

  43. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008;26(1):279–89. Epub 2007/10/27.

    Article  PubMed  CAS  Google Scholar 

  44. Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol. 2009;182(12):7963–73. Epub 2009/06/06.

    Article  PubMed  CAS  Google Scholar 

  45. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52. Epub 2007/04/18.

    Article  PubMed  CAS  Google Scholar 

  46. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-­natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107(4):1484–90. Epub 2005/10/22.

    Article  PubMed  CAS  Google Scholar 

  47. Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell. 2008;2(2):106–8. Epub 2008/03/29.

    Article  PubMed  CAS  Google Scholar 

  48. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92(7):881–8. Epub 2007/07/04.

    Article  PubMed  CAS  Google Scholar 

  49. Sundin M, Barrett AJ, Ringden O, Uzunel M, Lonnies H, Dackland AL, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother. 2009;32(7):755–64. Epub 2009/06/30.

    Article  PubMed  CAS  Google Scholar 

  50. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let’s not overlook some essential precautions. Blood. 2007;109(8):3147–51. Epub 2006/12/16.

    Article  PubMed  CAS  Google Scholar 

  51. Ball L, Bredius R, Lankester A, Schweizer J, van den Heuvel-Eibrink M, Escher H, et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia. 2008;22(6):1256–7. Epub 2007/11/02.

    Article  PubMed  CAS  Google Scholar 

  52. Lee MJ, Kim J, Kim MY, Bae YS, Ryu SH, Lee TG, et al. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J Proteome Res. 2010;9(4):1754–62. Epub 2010/02/27.

    Article  PubMed  CAS  Google Scholar 

  53. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K, et al. Action at a distance: ­systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells. 2011;29(10):1572–9. Epub 2011/08/13.

    Article  PubMed  CAS  Google Scholar 

  54. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 2006;24(4):1030–41. Epub 2005/10/29.

    Article  PubMed  CAS  Google Scholar 

  55. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006;24(4):1095–103. Epub 2005/11/12.

    Article  PubMed  Google Scholar 

  56. Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia. 2011;25(4):648–54. Epub 2011/01/19.

    Article  PubMed  CAS  Google Scholar 

  57. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-­host disease in mice. J Immunol. 2006;176(12):7761–7. Epub 2006/06/06.

    PubMed  CAS  Google Scholar 

  58. Chung NG, Jeong DC, Park SJ, Choi BO, Cho B, Kim HK, et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol. 2004;80(4):370–6. Epub 2004/12/24.

    Article  PubMed  Google Scholar 

  59. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21(9):1992–9. Epub 2007/07/13.

    Article  PubMed  CAS  Google Scholar 

  60. Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(10):637–45. Epub 2007/03/21.

    Article  PubMed  CAS  Google Scholar 

  61. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38(6):1745–55. Epub 2008/05/22.

    Article  PubMed  CAS  Google Scholar 

  62. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res. 2007;27(1):53–64. Epub 2007/02/03.

    Article  PubMed  CAS  Google Scholar 

  63. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002;29(12):979–86. Epub 2002/07/05.

    Article  PubMed  CAS  Google Scholar 

  64. Wang L, Li Y, Chen X, Chen J, Gautam SC, Xu Y, et al. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology. 2002;7(2):113–7. Epub 2002/08/21.

    Article  PubMed  CAS  Google Scholar 

  65. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy. 2010;12(3):361–70. Epub 2010/01/19.

    Article  PubMed  CAS  Google Scholar 

  66. Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+ CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008;7(6):608–14. Epub 2008/12/17.

    PubMed  Google Scholar 

  67. Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):241–8. Epub 2009/01/07.

    Article  PubMed  CAS  Google Scholar 

  68. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181(6):3933–46. Epub 2008/09/05.

    PubMed  CAS  Google Scholar 

  69. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36(3):309–18. Epub 2008/02/19.

    Article  PubMed  Google Scholar 

  70. Christensen ME, Turner BE, Sinfield LJ, Kollar K, Cullup H, Waterhouse NJ, et al. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica. 2010;95(12):2102–10. Epub 2010/08/31.

    Article  PubMed  Google Scholar 

  71. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, et al. Bioimaging to monitor the in vivo distribution of infused mesenchymal stem cells: in a mouse model of graft versus host disease. Cell Biol Int. 2011;35(4):417–21. Epub 2010/11/11.

    Article  PubMed  Google Scholar 

  72. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169(1):12–20. Epub 2001/05/08.

    Article  PubMed  CAS  Google Scholar 

  73. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-­inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63. Epub 2009/07/03.

    Article  PubMed  CAS  Google Scholar 

  74. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-­derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24(11):2582–91. Epub 2006/07/29.

    Article  PubMed  CAS  Google Scholar 

  75. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(7):804–11. Epub 2009/06/23.

    Article  PubMed  CAS  Google Scholar 

  76. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390–7.

    Article  PubMed  Google Scholar 

  77. Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc. 2007;39(5):1710–3. Epub 2007/06/21.

    Article  PubMed  CAS  Google Scholar 

  78. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86. Epub 2008/05/13.

    Article  PubMed  Google Scholar 

  79. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43(3):245–51. Epub 2008/09/30.

    Article  Google Scholar 

  80. Kurtzberg J, Prasad V, Grimley MS, Horn B, Carpenter PA, Jacobsen D, Prockop S, editors. Allogeneic human mesenchymal stem cell therapy (prochymal) as a rescue agent for severe treatment resistant GVHD in pediatric patients. Orlando: American Society of Blood and Marrow Transplantation; 2009.

    Google Scholar 

  81. Martin BJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P, editors. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-­controlled, multicenter phase III trial in GVHD. Orlando: American Society of Bone Marrow Transplantation; 2010.

    Google Scholar 

  82. Perez-Simon JA, Lopez-Villar O, Andreu EJ, Rifon J, Muntion S, Campelo MD, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011;96(7):1072–6. Epub 2011/03/12.

    Article  PubMed  Google Scholar 

  83. Martino Introna GL, Dander E, Rovelli A, Balduzzi A, Daniela L, Pavan F, Masciochi F, Algarotti A, Micò C, Grassi A, Cavattoni I, Deola S, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani EM, Golay J, Gotti E, Capelli C, Cortelazzo S, D’Amico G, Biondi A, Rambaldi A, Biagi E, editors. Safe and effective treatment of graft versus host disease with platelet lysate-expanded human mesenchymal stromal cells: a phase 1 study on 47 adult and pediatric patients. Atlanta: American Society of Hematology; 2012.

    Google Scholar 

  84. te Boome CMM L, Lindemans CA, Van der Wagen LE, Cuijpers M, Slaper-Cortenbach I, Rozemuller H, Petersen EJ, Spierings E, Bierings M, Boelens JJ, Wulffraat N, Kuball JH, editors. Treatment of steroid resistant grade II to IV acute GVHD by infusion of mesenchymal stroma cells expanded with human plasma and platelet lysate – a phase I/II study. Atlanta: American Society of Hematology; 2012.

    Google Scholar 

  85. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):25–32. Epub 2007/09/18.

    Article  PubMed  Google Scholar 

  86. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16(3):403–12. Epub 2009/11/21.

    Article  PubMed  CAS  Google Scholar 

  87. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45(12):1732–40. Epub 2010/09/08.

    Article  PubMed  CAS  Google Scholar 

  88. Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy. 2011;13(3):262–8.

    Article  PubMed  Google Scholar 

  89. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–41.

    Article  PubMed  Google Scholar 

  90. Remberger M, Ringden O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol. 2012;96(6):822–4. Epub 2012/11/13.

    Article  PubMed  Google Scholar 

  91. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, et al. Platelet-lysate-­expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010;16(9):1293–301. Epub 2010/03/31.

    Article  PubMed  Google Scholar 

  92. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273–8. Epub 2008/10/04.

    Article  PubMed  CAS  Google Scholar 

  93. Dander E, Lucchini G, Vinci P, Introna M, Masciocchi F, Perseghin P, et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia. 2012;26(7):1681–4. Epub 2012/02/01.

    Article  PubMed  CAS  Google Scholar 

  94. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andre V, et al. Interleukin-17-­producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation. 2009;88(11):1261–72. Epub 2009/12/10.

    Article  PubMed  CAS  Google Scholar 

  95. Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41(8):2314–22. Epub 2011/06/16.

    Article  PubMed  CAS  Google Scholar 

  96. Zhao XY, Xu LL, Lu SY, Huang XJ. IL-17-producing T cells contribute to acute graft-versus-­host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol. 2011;41(2):514–26. Epub 2011/01/27.

    Article  PubMed  CAS  Google Scholar 

  97. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (prochymal(TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011;17(4):534–41. Epub 2010/05/12.

    Article  PubMed  CAS  Google Scholar 

  98. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16(4):557–64. Epub 1995/10/01.

    PubMed  CAS  Google Scholar 

  99. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. Epub 2012/11/08.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Partow Kebriaei, Simon Robinson, Ian McNiece & Elizabeth Shpall

Authors
  1. Partow Kebriaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian McNiece
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth Shpall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Partow Kebriaei .

Editor information

Editors and Affiliations

  1. Chinese Academy of Medical Sciences and Peking Union Medical College, Center of Excellence in Tissue Engineering, Institute of Basic Medical Sciences and School of Basic Medicine, 5 Dong Dan San Tiao, Beijing, 100005, China, People's Republic

    Robert Chunhua Zhao

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kebriaei, P., Robinson, S., McNiece, I., Shpall, E. (2013). Mesenchymal Stem Cells as Therapy for Graft Versus Host Disease: What Have We Learned?. In: Zhao, R. (eds) Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6716-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation